Professional
Added to YB: 2024-11-12
Pitch date: 2024-09-30
SDZ.SW [bullish]
Sandoz Group AG
+111.73%
current return
Author Info
No bio for this author
Company Info
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology.
Market Cap
CHF 39.2B
Pitch Price
CHF 34.17
Price Target
N/A
Dividend
1.09%
EV/EBITDA
21.91
P/E
43.33
EV/Sales
3.87
Sector
Pharmaceuticals
Category
growth
Artisan Global Discovery Fund New Position: Sandoz Group AG
SDZ.SW (new position): Global leader in generics & biosimilars, serving 100+ markets & 500M+ people. First to introduce oral penicillin (1951) & biosimilar (HGH). Key player in antibiotics. Set to benefit from biosimilar industry growth, improving growth profile & profitability due to higher margins.
Read full article (1 min)